SBEM (also known as MUCL1), which has been identified as a putative breast-specific gene, has been proposed to be a marker for predicting blood micrometastasis and response to neoadjuvant chemotherapy in breast cancer [24], is mainly expressed in breast and salivary glands, and is highly expressed in breast cancer tissues and metastatic lymph nodes [17]. This evidence concerns the gene MUCL1 and breast carcinoma.